| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Scleroderma, Systemic | 143 | 2023 | 446 | 16.690 |
Why?
|
| Lung Diseases, Interstitial | 34 | 2023 | 110 | 6.820 |
Why?
|
| Pulmonary Fibrosis | 27 | 2023 | 157 | 3.340 |
Why?
|
| Lung | 34 | 2023 | 849 | 2.400 |
Why?
|
| Fibroblasts | 24 | 2023 | 902 | 1.780 |
Why?
|
| Hypertension, Pulmonary | 17 | 2018 | 232 | 1.780 |
Why?
|
| Lung Diseases | 15 | 2016 | 175 | 1.610 |
Why?
|
| Eosinophilia-Myalgia Syndrome | 15 | 1997 | 24 | 1.490 |
Why?
|
| Thrombin | 9 | 2014 | 117 | 1.390 |
Why?
|
| Raynaud Disease | 8 | 2022 | 24 | 1.360 |
Why?
|
| Humans | 224 | 2022 | 68549 | 1.240 |
Why?
|
| Scleroderma, Localized | 4 | 2023 | 19 | 1.210 |
Why?
|
| Immunosuppressive Agents | 11 | 2022 | 514 | 1.110 |
Why?
|
| Bronchoalveolar Lavage Fluid | 13 | 2009 | 117 | 1.100 |
Why?
|
| Female | 144 | 2022 | 38021 | 1.030 |
Why?
|
| Autoantibodies | 12 | 2019 | 434 | 0.970 |
Why?
|
| Telangiectasis | 3 | 2022 | 6 | 0.930 |
Why?
|
| CREST Syndrome | 2 | 2022 | 5 | 0.890 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2022 | 9 | 0.870 |
Why?
|
| Cyclophosphamide | 11 | 2022 | 129 | 0.870 |
Why?
|
| Hepatocyte Growth Factor | 5 | 2016 | 63 | 0.850 |
Why?
|
| Adult | 91 | 2022 | 21379 | 0.850 |
Why?
|
| Male | 110 | 2022 | 37283 | 0.850 |
Why?
|
| Gingivitis | 2 | 2013 | 16 | 0.840 |
Why?
|
| Respiratory Function Tests | 18 | 2020 | 123 | 0.830 |
Why?
|
| Middle Aged | 84 | 2022 | 21119 | 0.800 |
Why?
|
| Tryptophan | 9 | 1997 | 65 | 0.730 |
Why?
|
| Antiphospholipid Syndrome | 9 | 2000 | 25 | 0.700 |
Why?
|
| Scleroderma, Diffuse | 5 | 2020 | 25 | 0.690 |
Why?
|
| Immediate-Early Proteins | 3 | 2008 | 63 | 0.680 |
Why?
|
| Osteoarthropathy, Secondary Hypertrophic | 1 | 2019 | 3 | 0.680 |
Why?
|
| Benzimidazoles | 2 | 2011 | 128 | 0.680 |
Why?
|
| Periostitis | 1 | 2019 | 4 | 0.680 |
Why?
|
| Voriconazole | 1 | 2019 | 11 | 0.680 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 3 | 2008 | 146 | 0.650 |
Why?
|
| Antifungal Agents | 1 | 2019 | 108 | 0.640 |
Why?
|
| Lung Transplantation | 1 | 2019 | 88 | 0.620 |
Why?
|
| Toothbrushing | 3 | 2013 | 21 | 0.620 |
Why?
|
| Dental Devices, Home Care | 3 | 2013 | 17 | 0.620 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2019 | 786 | 0.610 |
Why?
|
| Fetal Death | 6 | 1999 | 49 | 0.610 |
Why?
|
| Rheumatology | 6 | 2019 | 46 | 0.570 |
Why?
|
| Pregnancy | 27 | 2021 | 2334 | 0.570 |
Why?
|
| Gastrointestinal Diseases | 6 | 2016 | 107 | 0.560 |
Why?
|
| Antibodies, Antiphospholipid | 7 | 1998 | 29 | 0.560 |
Why?
|
| Abortion, Habitual | 5 | 2000 | 13 | 0.550 |
Why?
|
| Calcinosis | 3 | 2011 | 241 | 0.550 |
Why?
|
| Microscopy | 3 | 2013 | 64 | 0.540 |
Why?
|
| Caveolin 1 | 7 | 2014 | 59 | 0.530 |
Why?
|
| Tomography, X-Ray Computed | 11 | 2015 | 2324 | 0.530 |
Why?
|
| Aged | 48 | 2022 | 14842 | 0.520 |
Why?
|
| Macrophage Activation | 2 | 2014 | 75 | 0.490 |
Why?
|
| Biomarkers | 6 | 2013 | 1593 | 0.470 |
Why?
|
| Fasciitis | 5 | 1994 | 30 | 0.460 |
Why?
|
| Plant Oils | 5 | 1997 | 31 | 0.460 |
Why?
|
| Dyspnea | 4 | 2010 | 87 | 0.460 |
Why?
|
| Oral Hygiene | 1 | 2013 | 33 | 0.450 |
Why?
|
| Paintings | 2 | 2008 | 3 | 0.450 |
Why?
|
| Eosinophilia | 5 | 1994 | 47 | 0.450 |
Why?
|
| Myositis | 2 | 2011 | 24 | 0.450 |
Why?
|
| Brassica | 4 | 1994 | 13 | 0.450 |
Why?
|
| Lupus Erythematosus, Systemic | 9 | 2013 | 756 | 0.450 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2013 | 237 | 0.450 |
Why?
|
| Famous Persons | 2 | 2008 | 15 | 0.450 |
Why?
|
| Exercise Therapy | 2 | 2011 | 183 | 0.430 |
Why?
|
| Lighting | 1 | 2012 | 9 | 0.420 |
Why?
|
| Image Enhancement | 2 | 2013 | 143 | 0.410 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 3 | 2019 | 66 | 0.410 |
Why?
|
| Heart Diseases | 3 | 2013 | 276 | 0.410 |
Why?
|
| Scleroderma, Limited | 2 | 2013 | 5 | 0.400 |
Why?
|
| Microstomia | 1 | 2011 | 5 | 0.400 |
Why?
|
| Antirheumatic Agents | 4 | 2022 | 58 | 0.400 |
Why?
|
| Pulmonary Artery | 1 | 2014 | 323 | 0.390 |
Why?
|
| Protein Kinase C | 6 | 2005 | 270 | 0.390 |
Why?
|
| Myofunctional Therapy | 1 | 2011 | 6 | 0.390 |
Why?
|
| Antithrombins | 2 | 2011 | 32 | 0.390 |
Why?
|
| beta-Alanine | 1 | 2011 | 20 | 0.390 |
Why?
|
| Proto-Oncogene Proteins c-met | 3 | 2016 | 33 | 0.390 |
Why?
|
| Mixed Connective Tissue Disease | 2 | 2010 | 9 | 0.390 |
Why?
|
| Spine | 1 | 2011 | 46 | 0.380 |
Why?
|
| Arthritis, Rheumatoid | 6 | 2019 | 155 | 0.380 |
Why?
|
| Registries | 5 | 2018 | 730 | 0.380 |
Why?
|
| Anticoagulants | 2 | 2014 | 356 | 0.380 |
Why?
|
| Sensitivity and Specificity | 12 | 2017 | 1753 | 0.380 |
Why?
|
| Disease Progression | 13 | 2020 | 1037 | 0.370 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2010 | 57 | 0.370 |
Why?
|
| Antibodies, Antinuclear | 11 | 2014 | 171 | 0.360 |
Why?
|
| Fetal Diseases | 4 | 2015 | 64 | 0.350 |
Why?
|
| Myofibroblasts | 2 | 2023 | 60 | 0.350 |
Why?
|
| Pre-Eclampsia | 3 | 2020 | 202 | 0.350 |
Why?
|
| Transforming Growth Factor beta1 | 3 | 2017 | 126 | 0.350 |
Why?
|
| Immunoglobulin G | 9 | 2001 | 481 | 0.350 |
Why?
|
| Abortion, Spontaneous | 2 | 2021 | 17 | 0.350 |
Why?
|
| Algorithms | 2 | 2013 | 1195 | 0.350 |
Why?
|
| Mice | 20 | 2023 | 8474 | 0.340 |
Why?
|
| Animals | 28 | 2023 | 20880 | 0.340 |
Why?
|
| Collagen | 7 | 2015 | 636 | 0.340 |
Why?
|
| Fibrosis | 5 | 2017 | 371 | 0.330 |
Why?
|
| Health Status Disparities | 1 | 2012 | 326 | 0.330 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 6 | 2017 | 507 | 0.330 |
Why?
|
| Signal Transduction | 8 | 2017 | 2689 | 0.320 |
Why?
|
| Arthritis, Juvenile | 4 | 1990 | 70 | 0.310 |
Why?
|
| Medicine in the Arts | 1 | 2008 | 7 | 0.310 |
Why?
|
| Connective Tissue Growth Factor | 4 | 2009 | 76 | 0.310 |
Why?
|
| Cell Movement | 3 | 2014 | 630 | 0.310 |
Why?
|
| Sick Role | 1 | 2008 | 40 | 0.310 |
Why?
|
| Pyridines | 1 | 2009 | 261 | 0.300 |
Why?
|
| Gastroesophageal Reflux | 1 | 2010 | 318 | 0.300 |
Why?
|
| Pregnancy, Animal | 2 | 1997 | 27 | 0.300 |
Why?
|
| Endothelin-1 | 1 | 2008 | 122 | 0.300 |
Why?
|
| Skin Ulcer | 2 | 2014 | 19 | 0.290 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2015 | 239 | 0.290 |
Why?
|
| Young Adult | 15 | 2021 | 5710 | 0.280 |
Why?
|
| Cyclooxygenase Inhibitors | 2 | 2003 | 72 | 0.280 |
Why?
|
| Collagen Type I | 1 | 2007 | 175 | 0.280 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 3 | 2013 | 63 | 0.280 |
Why?
|
| Cells, Cultured | 17 | 2019 | 2673 | 0.280 |
Why?
|
| Pulmonary Alveoli | 7 | 2014 | 62 | 0.280 |
Why?
|
| Connective Tissue Diseases | 2 | 2019 | 18 | 0.280 |
Why?
|
| Cell Proliferation | 2 | 2013 | 1174 | 0.270 |
Why?
|
| Proteomics | 1 | 2008 | 246 | 0.270 |
Why?
|
| Pregnancy Complications | 6 | 1997 | 286 | 0.270 |
Why?
|
| Solvents | 3 | 2001 | 109 | 0.270 |
Why?
|
| Antibodies, Anticardiolipin | 5 | 1999 | 15 | 0.270 |
Why?
|
| Treatment Outcome | 17 | 2016 | 7028 | 0.260 |
Why?
|
| Cross-Sectional Studies | 7 | 2017 | 2265 | 0.260 |
Why?
|
| Mucin-1 | 2 | 2019 | 35 | 0.260 |
Why?
|
| Skin Diseases | 5 | 1996 | 122 | 0.260 |
Why?
|
| Prospective Studies | 15 | 2021 | 3703 | 0.260 |
Why?
|
| Hospitalization | 2 | 2018 | 977 | 0.250 |
Why?
|
| Disease Models, Animal | 9 | 2017 | 2550 | 0.250 |
Why?
|
| Atherosclerosis | 3 | 2013 | 204 | 0.250 |
Why?
|
| Bleomycin | 4 | 2014 | 67 | 0.250 |
Why?
|
| Receptors, Cell Surface | 2 | 2011 | 248 | 0.250 |
Why?
|
| Mice, Inbred C57BL | 10 | 2017 | 2791 | 0.250 |
Why?
|
| Genetic Loci | 2 | 2016 | 59 | 0.250 |
Why?
|
| Retrospective Studies | 11 | 2022 | 7268 | 0.250 |
Why?
|
| Prognosis | 7 | 2017 | 2093 | 0.250 |
Why?
|
| Vasodilator Agents | 1 | 2005 | 138 | 0.240 |
Why?
|
| Diagnosis, Differential | 7 | 2010 | 1140 | 0.240 |
Why?
|
| Hyaluronan Receptors | 2 | 2017 | 142 | 0.240 |
Why?
|
| Hip Joint | 2 | 2003 | 64 | 0.240 |
Why?
|
| Transforming Growth Factor beta | 5 | 2014 | 384 | 0.240 |
Why?
|
| Silicones | 2 | 1995 | 32 | 0.240 |
Why?
|
| Piperazines | 1 | 2005 | 206 | 0.230 |
Why?
|
| Keloid | 1 | 2003 | 10 | 0.230 |
Why?
|
| Quality of Life | 6 | 2012 | 1515 | 0.230 |
Why?
|
| Vital Capacity | 9 | 2019 | 43 | 0.230 |
Why?
|
| Rheumatic Diseases | 2 | 2021 | 35 | 0.230 |
Why?
|
| Mouthwashes | 2 | 2013 | 9 | 0.230 |
Why?
|
| Hospital Mortality | 2 | 2005 | 384 | 0.230 |
Why?
|
| Amniotic Fluid | 2 | 1993 | 30 | 0.230 |
Why?
|
| Mammaplasty | 2 | 1995 | 41 | 0.230 |
Why?
|
| Premature Birth | 2 | 2020 | 150 | 0.230 |
Why?
|
| Aspirin | 4 | 2020 | 295 | 0.230 |
Why?
|
| Isoantibodies | 2 | 2000 | 35 | 0.230 |
Why?
|
| Down-Regulation | 5 | 2013 | 447 | 0.230 |
Why?
|
| Depression | 3 | 2013 | 942 | 0.230 |
Why?
|
| Xerostomia | 2 | 2013 | 24 | 0.230 |
Why?
|
| Infant, Small for Gestational Age | 2 | 1993 | 46 | 0.220 |
Why?
|
| Dental Care | 2 | 2013 | 34 | 0.220 |
Why?
|
| Musculoskeletal Diseases | 1 | 2003 | 45 | 0.220 |
Why?
|
| Co-Repressor Proteins | 1 | 2023 | 8 | 0.220 |
Why?
|
| Adolescent | 21 | 2021 | 8904 | 0.220 |
Why?
|
| LIM Domain Proteins | 1 | 2023 | 15 | 0.220 |
Why?
|
| Up-Regulation | 3 | 2008 | 682 | 0.220 |
Why?
|
| Mouth | 2 | 2013 | 64 | 0.220 |
Why?
|
| Osteoarthritis | 1 | 2003 | 73 | 0.220 |
Why?
|
| Double-Blind Method | 11 | 2020 | 1738 | 0.220 |
Why?
|
| Motor Skills | 2 | 2013 | 88 | 0.220 |
Why?
|
| Actins | 6 | 2013 | 249 | 0.220 |
Why?
|
| Biopsy | 6 | 2010 | 539 | 0.220 |
Why?
|
| Cell Culture Techniques | 3 | 2008 | 189 | 0.220 |
Why?
|
| Peptide Fragments | 5 | 2016 | 483 | 0.210 |
Why?
|
| HIV Infections | 1 | 2010 | 775 | 0.210 |
Why?
|
| Skin | 14 | 2015 | 451 | 0.210 |
Why?
|
| Dental Plaque Index | 2 | 2013 | 10 | 0.210 |
Why?
|
| Heptanoic Acids | 2 | 2013 | 28 | 0.210 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2011 | 626 | 0.210 |
Why?
|
| HLA Antigens | 3 | 2019 | 82 | 0.210 |
Why?
|
| Pulmonary Diffusing Capacity | 4 | 2014 | 12 | 0.210 |
Why?
|
| Th1 Cells | 1 | 2022 | 101 | 0.210 |
Why?
|
| Prednisone | 6 | 2009 | 104 | 0.200 |
Why?
|
| Oral Health | 2 | 2013 | 49 | 0.200 |
Why?
|
| Pyrroles | 2 | 2013 | 83 | 0.200 |
Why?
|
| Cytokines | 4 | 2011 | 866 | 0.200 |
Why?
|
| Indoles | 2 | 2019 | 146 | 0.200 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2001 | 62 | 0.200 |
Why?
|
| Antihypertensive Agents | 2 | 2008 | 497 | 0.200 |
Why?
|
| Pyrazoles | 2 | 2020 | 190 | 0.200 |
Why?
|
| Pyrimidines | 2 | 2020 | 178 | 0.200 |
Why?
|
| Hospitals, Community | 1 | 2001 | 64 | 0.200 |
Why?
|
| Hospital Charges | 1 | 2001 | 60 | 0.200 |
Why?
|
| Reference Values | 6 | 2007 | 579 | 0.190 |
Why?
|
| Receptor, PAR-1 | 4 | 2014 | 30 | 0.190 |
Why?
|
| Risk Factors | 14 | 2018 | 5720 | 0.190 |
Why?
|
| Cardiac Catheterization | 4 | 2017 | 419 | 0.190 |
Why?
|
| Isoenzymes | 3 | 2005 | 308 | 0.190 |
Why?
|
| Glycoproteins | 2 | 1999 | 238 | 0.190 |
Why?
|
| Reproducibility of Results | 6 | 2014 | 2077 | 0.190 |
Why?
|
| Immunization, Passive | 2 | 1997 | 24 | 0.190 |
Why?
|
| Radiography, Thoracic | 4 | 2014 | 99 | 0.190 |
Why?
|
| Epoprostenol | 1 | 2000 | 71 | 0.180 |
Why?
|
| Dabigatran | 2 | 2011 | 35 | 0.180 |
Why?
|
| Enzyme Activators | 1 | 2020 | 14 | 0.180 |
Why?
|
| Vascular Diseases | 4 | 2010 | 94 | 0.180 |
Why?
|
| Hypertension, Portal | 1 | 2021 | 53 | 0.180 |
Why?
|
| Monocytes | 4 | 2014 | 210 | 0.180 |
Why?
|
| Child | 12 | 2021 | 6401 | 0.180 |
Why?
|
| Dermatomyositis | 6 | 2019 | 31 | 0.180 |
Why?
|
| Pediatrics | 1 | 2003 | 341 | 0.180 |
Why?
|
| Mycophenolic Acid | 2 | 2019 | 62 | 0.180 |
Why?
|
| Macrophages | 3 | 2011 | 647 | 0.180 |
Why?
|
| Hemodynamics | 2 | 2016 | 705 | 0.180 |
Why?
|
| Platelet-Derived Growth Factor | 4 | 1995 | 45 | 0.180 |
Why?
|
| Kidney Diseases | 4 | 2016 | 307 | 0.180 |
Why?
|
| Molecular Mimicry | 1 | 2019 | 13 | 0.180 |
Why?
|
| Follow-Up Studies | 11 | 2020 | 3256 | 0.180 |
Why?
|
| Interleukin-8 | 1 | 2000 | 71 | 0.180 |
Why?
|
| Chemokines, CC | 1 | 2019 | 18 | 0.180 |
Why?
|
| Exercise Test | 3 | 2009 | 242 | 0.180 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2019 | 929 | 0.180 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2019 | 331 | 0.180 |
Why?
|
| Autocrine Communication | 2 | 2017 | 37 | 0.170 |
Why?
|
| Risk Assessment | 5 | 2020 | 2004 | 0.170 |
Why?
|
| Cannabis | 1 | 2021 | 115 | 0.170 |
Why?
|
| Patient Education as Topic | 2 | 2013 | 424 | 0.170 |
Why?
|
| Autoantigens | 1 | 2019 | 91 | 0.170 |
Why?
|
| Thrombocytopenia | 1 | 2000 | 122 | 0.170 |
Why?
|
| Bronchoalveolar Lavage | 3 | 2008 | 15 | 0.170 |
Why?
|
| Postoperative Complications | 2 | 2019 | 1615 | 0.170 |
Why?
|
| Genome-Wide Association Study | 2 | 2018 | 240 | 0.170 |
Why?
|
| South Carolina | 6 | 2017 | 2752 | 0.170 |
Why?
|
| Endothelium, Vascular | 3 | 2013 | 371 | 0.160 |
Why?
|
| Smad2 Protein | 2 | 2015 | 42 | 0.160 |
Why?
|
| United States | 10 | 2019 | 7338 | 0.160 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2018 | 245 | 0.160 |
Why?
|
| Pregnancy Outcome | 6 | 2020 | 157 | 0.160 |
Why?
|
| Length of Stay | 1 | 2001 | 780 | 0.150 |
Why?
|
| Cell Differentiation | 5 | 2017 | 1034 | 0.150 |
Why?
|
| Gene Regulatory Networks | 1 | 2018 | 94 | 0.150 |
Why?
|
| Self-Management | 1 | 2019 | 82 | 0.150 |
Why?
|
| Severity of Illness Index | 7 | 2020 | 1851 | 0.150 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2020 | 1745 | 0.150 |
Why?
|
| Weight Loss | 2 | 2017 | 319 | 0.150 |
Why?
|
| Kynurenine | 3 | 1992 | 36 | 0.150 |
Why?
|
| Relaxin | 2 | 2009 | 30 | 0.150 |
Why?
|
| Penicillamine | 2 | 1989 | 10 | 0.150 |
Why?
|
| Emergency Service, Hospital | 1 | 2003 | 711 | 0.150 |
Why?
|
| Spinal Diseases | 1 | 1997 | 53 | 0.150 |
Why?
|
| Fibronectins | 4 | 1992 | 130 | 0.140 |
Why?
|
| Infant, Newborn | 7 | 2007 | 2455 | 0.140 |
Why?
|
| Ulcer | 1 | 2016 | 27 | 0.140 |
Why?
|
| Weight Gain | 1 | 2017 | 135 | 0.140 |
Why?
|
| Alleles | 4 | 2019 | 386 | 0.140 |
Why?
|
| Treatment Failure | 3 | 2020 | 216 | 0.140 |
Why?
|
| NADPH Oxidases | 1 | 2017 | 80 | 0.140 |
Why?
|
| Apoptosis | 5 | 2014 | 1641 | 0.140 |
Why?
|
| Alveolar Epithelial Cells | 1 | 2016 | 28 | 0.140 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2016 | 101 | 0.140 |
Why?
|
| Self Care | 1 | 2019 | 252 | 0.140 |
Why?
|
| Idiopathic Interstitial Pneumonias | 1 | 2016 | 2 | 0.140 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 2 | 2007 | 82 | 0.140 |
Why?
|
| Fetoscopy | 1 | 2015 | 4 | 0.130 |
Why?
|
| Internet | 1 | 2019 | 390 | 0.130 |
Why?
|
| Databases, Factual | 3 | 2017 | 621 | 0.130 |
Why?
|
| Arm Injuries | 1 | 2015 | 13 | 0.130 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2017 | 117 | 0.130 |
Why?
|
| Pregnancy Complications, Hematologic | 1 | 1995 | 15 | 0.130 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 1995 | 14 | 0.130 |
Why?
|
| Catheters, Indwelling | 1 | 2015 | 72 | 0.130 |
Why?
|
| MAP Kinase Signaling System | 4 | 2014 | 247 | 0.130 |
Why?
|
| Pleural Effusion | 1 | 2015 | 74 | 0.130 |
Why?
|
| Antibodies | 7 | 2017 | 241 | 0.130 |
Why?
|
| Cystic Fibrosis | 1 | 2019 | 283 | 0.130 |
Why?
|
| Suprachiasmatic Nucleus | 1 | 1995 | 7 | 0.130 |
Why?
|
| Fetal Tissue Transplantation | 1 | 1995 | 12 | 0.130 |
Why?
|
| Breast Implants | 1 | 1995 | 18 | 0.130 |
Why?
|
| Connective Tissue | 1 | 1995 | 61 | 0.130 |
Why?
|
| Environmental Exposure | 4 | 2001 | 269 | 0.130 |
Why?
|
| Hospitals, University | 2 | 2006 | 169 | 0.130 |
Why?
|
| C-Reactive Protein | 2 | 2013 | 180 | 0.120 |
Why?
|
| Thrombosis | 2 | 1994 | 218 | 0.120 |
Why?
|
| RNA Polymerase III | 2 | 2005 | 7 | 0.120 |
Why?
|
| Familial Primary Pulmonary Hypertension | 4 | 2017 | 25 | 0.120 |
Why?
|
| Automation | 1 | 2014 | 45 | 0.120 |
Why?
|
| Perception | 1 | 2016 | 189 | 0.120 |
Why?
|
| Administration, Oral | 3 | 2011 | 411 | 0.120 |
Why?
|
| Peptides | 1 | 2017 | 455 | 0.120 |
Why?
|
| Fatty Acids, Monounsaturated | 5 | 1997 | 29 | 0.120 |
Why?
|
| Cohort Studies | 5 | 2017 | 2356 | 0.120 |
Why?
|
| Prostheses and Implants | 2 | 1993 | 159 | 0.120 |
Why?
|
| Nanotechnology | 1 | 2015 | 109 | 0.120 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2014 | 37 | 0.120 |
Why?
|
| Umbilical Cord | 2 | 2013 | 19 | 0.120 |
Why?
|
| Immunoglobulin M | 5 | 2001 | 172 | 0.120 |
Why?
|
| RNA, Messenger | 5 | 2013 | 1663 | 0.120 |
Why?
|
| Transcription Factor CHOP | 1 | 2014 | 28 | 0.120 |
Why?
|
| Nanostructures | 1 | 2015 | 112 | 0.120 |
Why?
|
| Cognition Disorders | 2 | 1996 | 342 | 0.120 |
Why?
|
| Inflammation | 2 | 2011 | 1030 | 0.120 |
Why?
|
| Infusion Pumps | 1 | 2014 | 39 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2014 | 32 | 0.120 |
Why?
|
| Radiography | 3 | 2010 | 572 | 0.120 |
Why?
|
| Logistic Models | 5 | 2014 | 1419 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2014 | 56 | 0.120 |
Why?
|
| Endothelin Receptor Antagonists | 2 | 2016 | 17 | 0.120 |
Why?
|
| Pregnancy-Specific beta 1-Glycoproteins | 1 | 1993 | 1 | 0.120 |
Why?
|
| Fetal Distress | 1 | 1993 | 8 | 0.120 |
Why?
|
| Diagnosis-Related Groups | 1 | 2013 | 28 | 0.120 |
Why?
|
| Ventricular Dysfunction | 1 | 2013 | 15 | 0.120 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2014 | 82 | 0.110 |
Why?
|
| Warfarin | 1 | 2014 | 93 | 0.110 |
Why?
|
| Periodontal Index | 1 | 2013 | 10 | 0.110 |
Why?
|
| Gingival Hemorrhage | 1 | 2013 | 10 | 0.110 |
Why?
|
| Pattern Recognition, Automated | 1 | 2013 | 70 | 0.110 |
Why?
|
| Carbonated Beverages | 1 | 2013 | 9 | 0.110 |
Why?
|
| Case-Control Studies | 5 | 2016 | 1549 | 0.110 |
Why?
|
| Germany | 2 | 2008 | 67 | 0.110 |
Why?
|
| Physical Exertion | 1 | 1993 | 75 | 0.110 |
Why?
|
| Obstetric Labor, Premature | 1 | 1993 | 76 | 0.110 |
Why?
|
| Amnion | 2 | 2007 | 15 | 0.110 |
Why?
|
| Bone Marrow Cells | 2 | 2013 | 217 | 0.110 |
Why?
|
| Endoplasmic Reticulum | 1 | 2014 | 148 | 0.110 |
Why?
|
| GATA6 Transcription Factor | 1 | 2013 | 27 | 0.110 |
Why?
|
| Glucose Tolerance Test | 1 | 2013 | 75 | 0.110 |
Why?
|
| Silicon | 1 | 1993 | 20 | 0.110 |
Why?
|
| Lymphocytes | 2 | 1991 | 228 | 0.110 |
Why?
|
| Motor Activity | 1 | 1996 | 621 | 0.110 |
Why?
|
| Patient Satisfaction | 1 | 2016 | 378 | 0.110 |
Why?
|
| Cardiovascular System | 1 | 1993 | 85 | 0.110 |
Why?
|
| Vimentin | 2 | 2008 | 47 | 0.110 |
Why?
|
| Heart Valve Diseases | 1 | 2013 | 123 | 0.110 |
Why?
|
| Hand | 1 | 2013 | 90 | 0.110 |
Why?
|
| Capillaries | 5 | 1989 | 105 | 0.110 |
Why?
|
| Materials Testing | 1 | 2013 | 263 | 0.110 |
Why?
|
| History, 20th Century | 2 | 2008 | 248 | 0.110 |
Why?
|
| Puerperal Infection | 1 | 1992 | 15 | 0.110 |
Why?
|
| Cognition | 1 | 1996 | 512 | 0.110 |
Why?
|
| Streptococcus pyogenes | 1 | 1992 | 20 | 0.100 |
Why?
|
| Extracellular Matrix Proteins | 3 | 2018 | 144 | 0.100 |
Why?
|
| Social Adjustment | 1 | 2012 | 74 | 0.100 |
Why?
|
| Decision Support Techniques | 1 | 2014 | 191 | 0.100 |
Why?
|
| Diabetes, Gestational | 1 | 2013 | 81 | 0.100 |
Why?
|
| PPAR gamma | 1 | 2012 | 95 | 0.100 |
Why?
|
| Drug Delivery Systems | 1 | 2014 | 236 | 0.100 |
Why?
|
| Antigens, CD | 2 | 2011 | 230 | 0.100 |
Why?
|
| Interleukin-6 | 1 | 1993 | 330 | 0.100 |
Why?
|
| Streptococcal Infections | 1 | 1992 | 53 | 0.100 |
Why?
|
| Immune System Diseases | 1 | 2011 | 12 | 0.100 |
Why?
|
| Lipopolysaccharides | 1 | 1994 | 455 | 0.100 |
Why?
|
| Cardiomyopathies | 1 | 2013 | 167 | 0.100 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2018 | 627 | 0.100 |
Why?
|
| Phospholipids | 1 | 1992 | 108 | 0.100 |
Why?
|
| Sex Distribution | 2 | 2003 | 272 | 0.100 |
Why?
|
| Disease Susceptibility | 1 | 2012 | 179 | 0.100 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2013 | 333 | 0.100 |
Why?
|
| Fingers | 2 | 2016 | 39 | 0.100 |
Why?
|
| Forced Expiratory Volume | 2 | 2008 | 87 | 0.100 |
Why?
|
| Epithelial Cells | 1 | 2014 | 431 | 0.100 |
Why?
|
| Age Distribution | 2 | 2003 | 319 | 0.100 |
Why?
|
| Anticholesteremic Agents | 1 | 2012 | 49 | 0.100 |
Why?
|
| Mouth Rehabilitation | 1 | 2011 | 7 | 0.100 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2011 | 234 | 0.100 |
Why?
|
| Tooth | 1 | 2011 | 24 | 0.100 |
Why?
|
| Gingiva | 1 | 2011 | 34 | 0.100 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2011 | 27 | 0.100 |
Why?
|
| Proto-Oncogene Protein c-fli-1 | 2 | 2010 | 106 | 0.100 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2011 | 30 | 0.100 |
Why?
|
| Electronic Health Records | 1 | 2014 | 374 | 0.090 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2013 | 212 | 0.090 |
Why?
|
| Killer Cells, Lymphokine-Activated | 1 | 1990 | 11 | 0.090 |
Why?
|
| Blood Cells | 1 | 1990 | 27 | 0.090 |
Why?
|
| Neutrophils | 2 | 2007 | 204 | 0.090 |
Why?
|
| Pain Management | 1 | 2012 | 186 | 0.090 |
Why?
|
| Attitude to Health | 1 | 2013 | 403 | 0.090 |
Why?
|
| Nervous System Diseases | 1 | 2011 | 142 | 0.090 |
Why?
|
| Biomedical Research | 1 | 2014 | 310 | 0.090 |
Why?
|
| Phenotype | 4 | 2022 | 946 | 0.090 |
Why?
|
| Occupational Exposure | 3 | 2000 | 122 | 0.090 |
Why?
|
| Nanoparticles | 1 | 2013 | 254 | 0.090 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 3 | 2008 | 175 | 0.090 |
Why?
|
| Blood Coagulation | 1 | 2010 | 123 | 0.090 |
Why?
|
| Joint Diseases | 1 | 2010 | 37 | 0.090 |
Why?
|
| Transfection | 3 | 2008 | 782 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 2 | 2011 | 511 | 0.090 |
Why?
|
| Gene Expression Regulation | 4 | 2013 | 1293 | 0.090 |
Why?
|
| Aged, 80 and over | 4 | 2016 | 4843 | 0.090 |
Why?
|
| Surveys and Questionnaires | 5 | 2016 | 2798 | 0.090 |
Why?
|
| Health Education | 1 | 2012 | 279 | 0.090 |
Why?
|
| Syndrome | 4 | 1997 | 255 | 0.090 |
Why?
|
| Leukocytes | 1 | 2010 | 99 | 0.090 |
Why?
|
| Sarcoidosis | 1 | 1990 | 77 | 0.090 |
Why?
|
| Autoimmunity | 1 | 2010 | 118 | 0.090 |
Why?
|
| Cerclage, Cervical | 1 | 2009 | 11 | 0.090 |
Why?
|
| Equipment Design | 1 | 2011 | 500 | 0.090 |
Why?
|
| Transforming Growth Factors | 1 | 1989 | 12 | 0.090 |
Why?
|
| Microfilament Proteins | 2 | 2001 | 102 | 0.090 |
Why?
|
| Cervix Uteri | 1 | 2009 | 64 | 0.090 |
Why?
|
| Drug Eruptions | 1 | 1989 | 16 | 0.080 |
Why?
|
| Pulmonary Surfactant-Associated Protein D | 1 | 2009 | 15 | 0.080 |
Why?
|
| Carotid Artery, Common | 1 | 2009 | 25 | 0.080 |
Why?
|
| Tunica Intima | 1 | 2009 | 59 | 0.080 |
Why?
|
| Respiratory Insufficiency | 1 | 1990 | 76 | 0.080 |
Why?
|
| Elastic Tissue | 1 | 1989 | 28 | 0.080 |
Why?
|
| Immunohistochemistry | 4 | 2020 | 1174 | 0.080 |
Why?
|
| Quinolinic Acid | 3 | 1994 | 11 | 0.080 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2008 | 12 | 0.080 |
Why?
|
| Manometry | 1 | 2010 | 276 | 0.080 |
Why?
|
| Evidence-Based Medicine | 2 | 2009 | 438 | 0.080 |
Why?
|
| Linear Models | 2 | 2001 | 521 | 0.080 |
Why?
|
| Review Literature as Topic | 1 | 2008 | 24 | 0.080 |
Why?
|
| Physical Endurance | 1 | 2009 | 38 | 0.080 |
Why?
|
| Acute Disease | 1 | 2010 | 658 | 0.080 |
Why?
|
| Antigen-Antibody Complex | 3 | 1988 | 175 | 0.080 |
Why?
|
| Patient Compliance | 1 | 2011 | 402 | 0.080 |
Why?
|
| Autopsy | 1 | 2008 | 56 | 0.080 |
Why?
|
| Lupus Nephritis | 1 | 2010 | 193 | 0.080 |
Why?
|
| Lupus Coagulation Inhibitor | 3 | 1997 | 15 | 0.080 |
Why?
|
| Histocompatibility Antigens Class II | 2 | 2011 | 77 | 0.080 |
Why?
|
| Esophagus | 1 | 2010 | 303 | 0.080 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2000 | 52 | 0.080 |
Why?
|
| Exercise Tolerance | 1 | 2009 | 75 | 0.080 |
Why?
|
| Cordocentesis | 2 | 2000 | 2 | 0.080 |
Why?
|
| Health Status Indicators | 2 | 2007 | 117 | 0.080 |
Why?
|
| Switzerland | 1 | 2008 | 4 | 0.080 |
Why?
|
| Consensus | 3 | 2014 | 211 | 0.080 |
Why?
|
| Transplantation, Homologous | 3 | 2013 | 242 | 0.080 |
Why?
|
| Antigens, Differentiation | 2 | 2004 | 49 | 0.080 |
Why?
|
| Confidence Intervals | 2 | 2001 | 242 | 0.080 |
Why?
|
| Laser Coagulation | 1 | 2007 | 8 | 0.080 |
Why?
|
| Fetofetal Transfusion | 1 | 2007 | 3 | 0.080 |
Why?
|
| History, 19th Century | 1 | 2008 | 95 | 0.080 |
Why?
|
| Cardiovascular Diseases | 2 | 2010 | 938 | 0.080 |
Why?
|
| Leukocyte Count | 1 | 2007 | 94 | 0.080 |
Why?
|
| DNA | 3 | 2010 | 597 | 0.080 |
Why?
|
| Autoimmune Diseases | 2 | 2006 | 186 | 0.080 |
Why?
|
| Sulfonamides | 1 | 2008 | 141 | 0.080 |
Why?
|
| Echocardiography, Doppler | 2 | 2013 | 87 | 0.070 |
Why?
|
| Diseases in Twins | 1 | 2007 | 31 | 0.070 |
Why?
|
| Eosinophils | 1 | 2007 | 60 | 0.070 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2007 | 74 | 0.070 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2014 | 411 | 0.070 |
Why?
|
| Incidence | 3 | 2007 | 1582 | 0.070 |
Why?
|
| Clinical Trials as Topic | 2 | 2010 | 848 | 0.070 |
Why?
|
| Glucocorticoids | 3 | 2016 | 222 | 0.070 |
Why?
|
| Regression Analysis | 3 | 2017 | 737 | 0.070 |
Why?
|
| Disability Evaluation | 2 | 2007 | 298 | 0.070 |
Why?
|
| Arthritis | 1 | 1987 | 53 | 0.070 |
Why?
|
| Sex Factors | 3 | 2018 | 1265 | 0.070 |
Why?
|
| Wound Healing | 1 | 2008 | 260 | 0.070 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2007 | 320 | 0.070 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2008 | 306 | 0.070 |
Why?
|
| Mice, Inbred C3H | 2 | 1997 | 134 | 0.070 |
Why?
|
| Amino Acid Sequence | 2 | 2019 | 1082 | 0.070 |
Why?
|
| Total Lung Capacity | 2 | 2007 | 14 | 0.070 |
Why?
|
| Sildenafil Citrate | 1 | 2005 | 23 | 0.070 |
Why?
|
| Age of Onset | 1 | 2006 | 188 | 0.070 |
Why?
|
| Purines | 1 | 2005 | 39 | 0.070 |
Why?
|
| Sulfones | 1 | 2005 | 45 | 0.070 |
Why?
|
| NF-kappa B | 1 | 2007 | 432 | 0.060 |
Why?
|
| Caveolins | 1 | 2005 | 6 | 0.060 |
Why?
|
| Cell Survival | 3 | 2015 | 901 | 0.060 |
Why?
|
| Health Status | 2 | 2005 | 429 | 0.060 |
Why?
|
| Immunoglobulin Allotypes | 2 | 2001 | 82 | 0.060 |
Why?
|
| Europe | 2 | 2016 | 196 | 0.060 |
Why?
|
| Drug Administration Schedule | 3 | 2020 | 567 | 0.060 |
Why?
|
| Infant | 3 | 2003 | 2891 | 0.060 |
Why?
|
| Cell Division | 3 | 1995 | 541 | 0.060 |
Why?
|
| Echocardiography | 2 | 2018 | 515 | 0.060 |
Why?
|
| Creatinine | 3 | 2010 | 243 | 0.060 |
Why?
|
| Smoking | 1 | 2013 | 1449 | 0.060 |
Why?
|
| Demography | 1 | 2005 | 279 | 0.060 |
Why?
|
| Blotting, Northern | 2 | 1996 | 189 | 0.060 |
Why?
|
| Delphi Technique | 2 | 2016 | 62 | 0.060 |
Why?
|
| Child, Preschool | 3 | 2003 | 3187 | 0.060 |
Why?
|
| Risk | 2 | 2017 | 563 | 0.060 |
Why?
|
| Pulmonary Circulation | 1 | 2004 | 79 | 0.060 |
Why?
|
| Cyclosporine | 2 | 1996 | 121 | 0.060 |
Why?
|
| Protein Kinase C-epsilon | 4 | 2005 | 28 | 0.060 |
Why?
|
| Electron Probe Microanalysis | 2 | 1995 | 16 | 0.060 |
Why?
|
| Caspase 3 | 2 | 2015 | 233 | 0.060 |
Why?
|
| Dinoprostone | 2 | 1996 | 110 | 0.060 |
Why?
|
| Research Design | 3 | 2010 | 729 | 0.060 |
Why?
|
| RNA Polymerase I | 1 | 2003 | 5 | 0.060 |
Why?
|
| Curcumin | 1 | 2004 | 23 | 0.060 |
Why?
|
| Pregnancy-Associated Plasma Protein-A | 1 | 2003 | 3 | 0.060 |
Why?
|
| Muscle, Smooth | 2 | 1995 | 117 | 0.060 |
Why?
|
| Chorionic Gonadotropin, beta Subunit, Human | 1 | 2003 | 10 | 0.060 |
Why?
|
| Receptors, CXCR4 | 2 | 2014 | 48 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2003 | 17 | 0.060 |
Why?
|
| Transplantation, Heterologous | 2 | 2013 | 122 | 0.060 |
Why?
|
| Rheumatoid Factor | 1 | 2003 | 21 | 0.060 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 1 | 2003 | 10 | 0.060 |
Why?
|
| In Vitro Techniques | 4 | 2014 | 765 | 0.060 |
Why?
|
| Granulomatosis with Polyangiitis | 1 | 2003 | 11 | 0.060 |
Why?
|
| Microscopy, Electron | 2 | 1997 | 351 | 0.060 |
Why?
|
| Immunoenzyme Techniques | 2 | 2014 | 196 | 0.060 |
Why?
|
| Biopsy, Needle | 2 | 2020 | 191 | 0.060 |
Why?
|
| Trisomy | 1 | 2003 | 47 | 0.060 |
Why?
|
| Neck | 1 | 2003 | 62 | 0.060 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2004 | 144 | 0.060 |
Why?
|
| Prenatal Diagnosis | 1 | 2003 | 73 | 0.060 |
Why?
|
| Odds Ratio | 2 | 2005 | 880 | 0.060 |
Why?
|
| Nails | 4 | 1989 | 15 | 0.060 |
Why?
|
| Mice, Inbred Strains | 2 | 2008 | 181 | 0.050 |
Why?
|
| Lymphocyte Subsets | 1 | 2022 | 16 | 0.050 |
Why?
|
| beta 2-Glycoprotein I | 2 | 1999 | 10 | 0.050 |
Why?
|
| Th2 Cells | 1 | 2022 | 48 | 0.050 |
Why?
|
| Interleukin-4 | 1 | 2022 | 69 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2009 | 1465 | 0.050 |
Why?
|
| Fascia | 2 | 1994 | 17 | 0.050 |
Why?
|
| Muscle Contraction | 1 | 2003 | 210 | 0.050 |
Why?
|
| Carotid Intima-Media Thickness | 2 | 2013 | 54 | 0.050 |
Why?
|
| Forkhead Transcription Factors | 1 | 2022 | 94 | 0.050 |
Why?
|
| Down Syndrome | 1 | 2003 | 120 | 0.050 |
Why?
|
| Epitopes | 2 | 2005 | 146 | 0.050 |
Why?
|
| Trans-Activators | 1 | 2003 | 237 | 0.050 |
Why?
|
| Muscles | 2 | 1994 | 158 | 0.050 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2022 | 126 | 0.050 |
Why?
|
| Live Birth | 1 | 2021 | 8 | 0.050 |
Why?
|
| Fertility | 1 | 2021 | 60 | 0.050 |
Why?
|
| Academic Medical Centers | 1 | 2003 | 281 | 0.050 |
Why?
|
| Graft Survival | 2 | 2013 | 465 | 0.050 |
Why?
|
| Probability | 1 | 2001 | 244 | 0.050 |
Why?
|
| Fluorescent Antibody Technique | 6 | 2014 | 282 | 0.050 |
Why?
|
| Periodicals as Topic | 1 | 2003 | 158 | 0.050 |
Why?
|
| Blood Pressure | 2 | 2020 | 1449 | 0.050 |
Why?
|
| Mice, Knockout | 3 | 2013 | 1692 | 0.050 |
Why?
|
| Hyperplasia | 1 | 2021 | 89 | 0.050 |
Why?
|
| Liver Regeneration | 1 | 2021 | 38 | 0.050 |
Why?
|
| Breast | 2 | 1993 | 137 | 0.050 |
Why?
|
| Comorbidity | 1 | 2005 | 1425 | 0.050 |
Why?
|
| Survival Rate | 2 | 2018 | 1055 | 0.050 |
Why?
|
| Antigens, Human Platelet | 1 | 2000 | 1 | 0.050 |
Why?
|
| Cardiac Output | 1 | 2000 | 133 | 0.050 |
Why?
|
| Hemorrhage | 2 | 1995 | 328 | 0.050 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2022 | 266 | 0.050 |
Why?
|
| Umbilical Veins | 1 | 2000 | 54 | 0.050 |
Why?
|
| Polymorphism, Genetic | 1 | 2001 | 301 | 0.050 |
Why?
|
| Age Factors | 3 | 2013 | 1860 | 0.050 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2000 | 57 | 0.050 |
Why?
|
| Platelet Count | 1 | 2000 | 100 | 0.040 |
Why?
|
| Uterine Cervical Incompetence | 1 | 2000 | 4 | 0.040 |
Why?
|
| Receptors, Thrombin | 1 | 2000 | 18 | 0.040 |
Why?
|
| Phycodnaviridae | 1 | 2019 | 2 | 0.040 |
Why?
|
| Mimiviridae | 1 | 2019 | 2 | 0.040 |
Why?
|
| Chemotaxis | 1 | 2000 | 38 | 0.040 |
Why?
|
| Culture Media, Conditioned | 1 | 2000 | 78 | 0.040 |
Why?
|
| Hobbies | 1 | 1999 | 4 | 0.040 |
Why?
|
| Antigens, Viral | 1 | 2019 | 35 | 0.040 |
Why?
|
| Integrin beta3 | 1 | 2000 | 35 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2000 | 334 | 0.040 |
Why?
|
| Fetal Blood | 1 | 2000 | 131 | 0.040 |
Why?
|
| Hydrolysis | 1 | 2000 | 144 | 0.040 |
Why?
|
| Internationality | 1 | 2020 | 74 | 0.040 |
Why?
|
| Thrombophilia | 1 | 2000 | 21 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2019 | 52 | 0.040 |
Why?
|
| Delivery, Obstetric | 1 | 2020 | 58 | 0.040 |
Why?
|
| Linkage Disequilibrium | 2 | 2014 | 91 | 0.040 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2000 | 102 | 0.040 |
Why?
|
| Uterus | 1 | 2000 | 77 | 0.040 |
Why?
|
| Neuromuscular Diseases | 2 | 1996 | 14 | 0.040 |
Why?
|
| Cell Nucleus | 3 | 2013 | 305 | 0.040 |
Why?
|
| Protein Structure, Secondary | 1 | 2019 | 136 | 0.040 |
Why?
|
| Chromosome Aberrations | 1 | 2000 | 86 | 0.040 |
Why?
|
| Placebos | 2 | 2010 | 195 | 0.040 |
Why?
|
| DNA Primers | 1 | 2000 | 302 | 0.040 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2019 | 230 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2001 | 503 | 0.040 |
Why?
|
| DNA-Binding Proteins | 1 | 2003 | 700 | 0.040 |
Why?
|
| Ireland | 1 | 2019 | 13 | 0.040 |
Why?
|
| Sjogren's Syndrome | 1 | 2019 | 18 | 0.040 |
Why?
|
| Developing Countries | 1 | 2020 | 106 | 0.040 |
Why?
|
| Joints | 2 | 2010 | 30 | 0.040 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 2 | 1995 | 10 | 0.040 |
Why?
|
| Phosphorylation | 2 | 2016 | 1200 | 0.040 |
Why?
|
| Principal Component Analysis | 1 | 2018 | 55 | 0.040 |
Why?
|
| United Kingdom | 1 | 2019 | 152 | 0.040 |
Why?
|
| Cardiolipins | 1 | 1998 | 12 | 0.040 |
Why?
|
| Adenosine Triphosphatases | 1 | 2018 | 83 | 0.040 |
Why?
|
| Pregnancy Trimester, First | 2 | 2003 | 43 | 0.040 |
Why?
|
| Arterial Pressure | 1 | 2018 | 46 | 0.040 |
Why?
|
| Prevalence | 3 | 2017 | 1609 | 0.040 |
Why?
|
| Computational Biology | 1 | 2019 | 190 | 0.040 |
Why?
|
| Trichloroethylene | 2 | 1998 | 41 | 0.040 |
Why?
|
| Base Sequence | 1 | 2000 | 1015 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2018 | 38 | 0.040 |
Why?
|
| Limit of Detection | 1 | 2017 | 11 | 0.040 |
Why?
|
| Transplantation Conditioning | 1 | 2018 | 34 | 0.040 |
Why?
|
| Half-Life | 1 | 2017 | 96 | 0.040 |
Why?
|
| Lumbosacral Region | 1 | 1997 | 18 | 0.040 |
Why?
|
| Calibration | 1 | 2017 | 73 | 0.040 |
Why?
|
| Self Efficacy | 1 | 2019 | 199 | 0.040 |
Why?
|
| Organic Chemicals | 1 | 1998 | 77 | 0.040 |
Why?
|
| Microcirculation | 2 | 2010 | 77 | 0.040 |
Why?
|
| Longitudinal Studies | 2 | 2014 | 1054 | 0.040 |
Why?
|
| Transplantation, Autologous | 1 | 2018 | 145 | 0.040 |
Why?
|
| Chromosome Mapping | 1 | 2017 | 188 | 0.040 |
Why?
|
| Genetic Variation | 1 | 2018 | 220 | 0.040 |
Why?
|
| Macrophage Inflammatory Proteins | 1 | 1997 | 3 | 0.040 |
Why?
|
| Chemokine CCL4 | 1 | 1997 | 6 | 0.040 |
Why?
|
| Chemokine CCL3 | 1 | 1997 | 9 | 0.040 |
Why?
|
| Genotype | 2 | 2014 | 785 | 0.040 |
Why?
|
| NADPH Oxidase 4 | 1 | 2017 | 17 | 0.040 |
Why?
|
| Mass Screening | 2 | 2013 | 838 | 0.040 |
Why?
|
| Erythroblastosis, Fetal | 1 | 1997 | 3 | 0.040 |
Why?
|
| Rh Isoimmunization | 1 | 1997 | 6 | 0.040 |
Why?
|
| Immunogenetics | 2 | 2011 | 8 | 0.040 |
Why?
|
| Chemokine CCL5 | 1 | 1997 | 23 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2003 | 186 | 0.040 |
Why?
|
| Pain | 2 | 2012 | 472 | 0.040 |
Why?
|
| Transcription Factor AP-1 | 1 | 2017 | 61 | 0.040 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2017 | 56 | 0.040 |
Why?
|
| Prostaglandins I | 1 | 2016 | 1 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2018 | 349 | 0.040 |
Why?
|
| Procollagen | 1 | 1997 | 31 | 0.040 |
Why?
|
| Fluoxetine | 1 | 2016 | 40 | 0.040 |
Why?
|
| Fetus | 1 | 1997 | 157 | 0.040 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 1 | 2016 | 25 | 0.040 |
Why?
|
| Ultrasonography, Prenatal | 2 | 2009 | 79 | 0.040 |
Why?
|
| Nervous System | 1 | 1996 | 45 | 0.040 |
Why?
|
| A549 Cells | 1 | 2016 | 50 | 0.040 |
Why?
|
| Rats | 3 | 2013 | 5300 | 0.040 |
Why?
|
| Swimming | 1 | 1996 | 38 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2018 | 536 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 791 | 0.030 |
Why?
|
| Ventricular Function, Right | 1 | 2017 | 103 | 0.030 |
Why?
|
| Endothelial Cells | 2 | 2013 | 384 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2019 | 403 | 0.030 |
Why?
|
| In Situ Hybridization | 1 | 1996 | 201 | 0.030 |
Why?
|
| Maze Learning | 1 | 1996 | 138 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 1997 | 532 | 0.030 |
Why?
|
| Reaction Time | 1 | 1996 | 170 | 0.030 |
Why?
|
| Isomerism | 1 | 1995 | 63 | 0.030 |
Why?
|
| Arm | 1 | 2015 | 59 | 0.030 |
Why?
|
| Microscopy, Scanning Tunneling | 1 | 2015 | 1 | 0.030 |
Why?
|
| Neovascularization, Pathologic | 2 | 2004 | 183 | 0.030 |
Why?
|
| Printing | 1 | 2015 | 9 | 0.030 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2016 | 201 | 0.030 |
Why?
|
| Radioimmunoassay | 2 | 1993 | 164 | 0.030 |
Why?
|
| Therapeutic Irrigation | 2 | 1986 | 63 | 0.030 |
Why?
|
| Drainage | 1 | 2015 | 133 | 0.030 |
Why?
|
| Malabsorption Syndromes | 1 | 2014 | 7 | 0.030 |
Why?
|
| Chromosomes | 2 | 1985 | 17 | 0.030 |
Why?
|
| Centromere | 2 | 1985 | 15 | 0.030 |
Why?
|
| Protein Kinase C-alpha | 2 | 2005 | 24 | 0.030 |
Why?
|
| Cesarean Section | 1 | 1995 | 101 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 1997 | 614 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2019 | 1341 | 0.030 |
Why?
|
| Cricetinae | 1 | 1995 | 262 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2017 | 955 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2017 | 499 | 0.030 |
Why?
|
| False Positive Reactions | 2 | 2005 | 95 | 0.030 |
Why?
|
| Cell Communication | 1 | 1995 | 116 | 0.030 |
Why?
|
| Body Weight | 1 | 1996 | 554 | 0.030 |
Why?
|
| Documentation | 1 | 2014 | 83 | 0.030 |
Why?
|
| HLA-D Antigens | 1 | 2014 | 20 | 0.030 |
Why?
|
| Microchip Analytical Procedures | 1 | 2014 | 2 | 0.030 |
Why?
|
| Osmosis | 1 | 2014 | 38 | 0.030 |
Why?
|
| Endodeoxyribonucleases | 1 | 2014 | 8 | 0.030 |
Why?
|
| Occupational Diseases | 1 | 1994 | 68 | 0.030 |
Why?
|
| Autophagy-Related Protein 5 | 1 | 2014 | 11 | 0.030 |
Why?
|
| Interleukin-12 Subunit p35 | 1 | 2014 | 6 | 0.030 |
Why?
|
| Cytoskeleton | 1 | 2014 | 84 | 0.030 |
Why?
|
| Epigenomics | 1 | 2014 | 29 | 0.030 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2014 | 20 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 1996 | 1040 | 0.030 |
Why?
|
| Matrix Attachment Regions | 1 | 2013 | 4 | 0.030 |
Why?
|
| beta Catenin | 1 | 2014 | 73 | 0.030 |
Why?
|
| Cerebral Hemorrhage | 1 | 1995 | 198 | 0.030 |
Why?
|
| Circadian Rhythm | 1 | 1995 | 218 | 0.030 |
Why?
|
| Decidua | 1 | 1993 | 8 | 0.030 |
Why?
|
| Smad3 Protein | 1 | 2013 | 33 | 0.030 |
Why?
|
| Culture Media | 1 | 2013 | 155 | 0.030 |
Why?
|
| Lymphatic Diseases | 1 | 1993 | 27 | 0.030 |
Why?
|
| Thromboxane B2 | 1 | 1993 | 108 | 0.030 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2014 | 99 | 0.030 |
Why?
|
| Aryl Hydrocarbon Receptor Nuclear Translocator | 1 | 2013 | 7 | 0.030 |
Why?
|
| Hypertrophy, Right Ventricular | 1 | 2013 | 21 | 0.030 |
Why?
|
| Molecular Sequence Data | 1 | 2015 | 1446 | 0.030 |
Why?
|
| Puberty | 1 | 2013 | 10 | 0.030 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2014 | 114 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 1995 | 244 | 0.030 |
Why?
|
| Esophageal Diseases | 1 | 1993 | 95 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 209 | 0.030 |
Why?
|
| Desmin | 1 | 1992 | 13 | 0.030 |
Why?
|
| Gels | 1 | 1993 | 55 | 0.030 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2013 | 58 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2013 | 110 | 0.030 |
Why?
|
| Carotid Arteries | 1 | 2013 | 110 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 1 | 2013 | 322 | 0.030 |
Why?
|
| Serum Albumin | 1 | 2013 | 104 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2013 | 489 | 0.030 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2013 | 28 | 0.030 |
Why?
|
| Oxygen Consumption | 1 | 1993 | 258 | 0.030 |
Why?
|
| Gestational Age | 1 | 1993 | 389 | 0.030 |
Why?
|
| Cholesterol, LDL | 1 | 2013 | 161 | 0.030 |
Why?
|
| Chronic Disease | 2 | 2013 | 1329 | 0.030 |
Why?
|
| Enzyme Activation | 2 | 2005 | 791 | 0.030 |
Why?
|
| Neopterin | 1 | 1992 | 2 | 0.030 |
Why?
|
| Quinolinic Acids | 1 | 1992 | 6 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 2 | 2013 | 772 | 0.030 |
Why?
|
| Biopterin | 1 | 1992 | 10 | 0.030 |
Why?
|
| Pneumonia | 1 | 2013 | 110 | 0.030 |
Why?
|
| Prosthesis Failure | 1 | 1993 | 130 | 0.030 |
Why?
|
| Hypoxia | 1 | 2013 | 169 | 0.030 |
Why?
|
| Escherichia coli | 1 | 1994 | 368 | 0.030 |
Why?
|
| Cytoskeletal Proteins | 1 | 1992 | 108 | 0.030 |
Why?
|
| Adaptation, Physiological | 1 | 2013 | 189 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2014 | 652 | 0.030 |
Why?
|
| Disease Management | 1 | 2013 | 248 | 0.030 |
Why?
|
| Blood Cell Count | 1 | 1991 | 35 | 0.030 |
Why?
|
| Heparin | 1 | 1992 | 205 | 0.020 |
Why?
|
| HLA-DRB1 Chains | 1 | 2011 | 21 | 0.020 |
Why?
|
| Complement System Proteins | 1 | 2013 | 135 | 0.020 |
Why?
|
| Recombinant Proteins | 2 | 2009 | 742 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 1992 | 241 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2013 | 285 | 0.020 |
Why?
|
| Heart Rate | 1 | 1993 | 568 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2011 | 207 | 0.020 |
Why?
|
| Lipoprotein(a) | 1 | 2010 | 9 | 0.020 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 1990 | 22 | 0.020 |
Why?
|
| Quality of Health Care | 1 | 2013 | 322 | 0.020 |
Why?
|
| Silicone Elastomers | 1 | 1990 | 17 | 0.020 |
Why?
|
| Life Style | 1 | 2013 | 338 | 0.020 |
Why?
|
| Adaptive Immunity | 1 | 2011 | 37 | 0.020 |
Why?
|
| Uveitis | 1 | 1990 | 13 | 0.020 |
Why?
|
| Complement C4 | 1 | 2010 | 15 | 0.020 |
Why?
|
| HMGB1 Protein | 1 | 2010 | 23 | 0.020 |
Why?
|
| Surgery, Plastic | 1 | 1990 | 14 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2014 | 597 | 0.020 |
Why?
|
| Synovitis | 1 | 2010 | 8 | 0.020 |
Why?
|
| Fibrillins | 2 | 2001 | 24 | 0.020 |
Why?
|
| Fibrillin-1 | 2 | 2001 | 18 | 0.020 |
Why?
|
| Neutrophil Infiltration | 1 | 2010 | 35 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 2 | 1988 | 124 | 0.020 |
Why?
|
| Hydroxyindoleacetic Acid | 1 | 1990 | 36 | 0.020 |
Why?
|
| Mice, Inbred MRL lpr | 1 | 2010 | 118 | 0.020 |
Why?
|
| Gallium Radioisotopes | 1 | 1990 | 5 | 0.020 |
Why?
|
| Citrates | 1 | 1990 | 7 | 0.020 |
Why?
|
| Primary Health Care | 1 | 2016 | 702 | 0.020 |
Why?
|
| Chemokines | 1 | 2011 | 119 | 0.020 |
Why?
|
| Citric Acid | 1 | 1990 | 16 | 0.020 |
Why?
|
| Lipoproteins, HDL | 1 | 2010 | 113 | 0.020 |
Why?
|
| Killer Cells, Natural | 1 | 1990 | 94 | 0.020 |
Why?
|
| Triglycerides | 1 | 2010 | 184 | 0.020 |
Why?
|
| Blood Gas Analysis | 1 | 1990 | 41 | 0.020 |
Why?
|
| Tendons | 1 | 2010 | 45 | 0.020 |
Why?
|
| Lipids | 1 | 2012 | 298 | 0.020 |
Why?
|
| Endpoint Determination | 1 | 2010 | 82 | 0.020 |
Why?
|
| Recurrence | 1 | 2013 | 948 | 0.020 |
Why?
|
| Complement C3 | 1 | 2010 | 101 | 0.020 |
Why?
|
| Chemokine CCL2 | 1 | 2010 | 101 | 0.020 |
Why?
|
| Immunity, Innate | 1 | 2011 | 156 | 0.020 |
Why?
|
| Polyarteritis Nodosa | 1 | 1989 | 9 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 1990 | 133 | 0.020 |
Why?
|
| Proteinuria | 1 | 2010 | 136 | 0.020 |
Why?
|
| Permeability | 1 | 2010 | 131 | 0.020 |
Why?
|
| Cell Count | 1 | 1990 | 248 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 1990 | 166 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2010 | 186 | 0.020 |
Why?
|
| Bone Marrow Transplantation | 1 | 2010 | 149 | 0.020 |
Why?
|
| Time Factors | 2 | 2009 | 4655 | 0.020 |
Why?
|
| Pregnancy Trimester, Second | 1 | 2009 | 58 | 0.020 |
Why?
|
| Range of Motion, Articular | 1 | 2010 | 139 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2013 | 631 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2013 | 413 | 0.020 |
Why?
|
| Azathioprine | 1 | 2009 | 16 | 0.020 |
Why?
|
| Infusions, Subcutaneous | 1 | 2009 | 5 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2011 | 714 | 0.020 |
Why?
|
| Pulmonary Gas Exchange | 1 | 2009 | 20 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2014 | 1851 | 0.020 |
Why?
|
| Respiratory Physiological Phenomena | 1 | 2009 | 10 | 0.020 |
Why?
|
| Carotid Artery Diseases | 1 | 1989 | 83 | 0.020 |
Why?
|
| Cholesterol | 1 | 2010 | 331 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2009 | 238 | 0.020 |
Why?
|
| Bronchoscopy | 1 | 1990 | 147 | 0.020 |
Why?
|
| Intracranial Aneurysm | 1 | 1989 | 87 | 0.020 |
Why?
|
| Lipoproteins | 1 | 2009 | 161 | 0.020 |
Why?
|
| Leukemia, Lymphoid | 1 | 1988 | 17 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2009 | 291 | 0.020 |
Why?
|
| Lipoproteins, LDL | 1 | 2010 | 343 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2013 | 2083 | 0.020 |
Why?
|
| Receptors, Fc | 1 | 1988 | 19 | 0.020 |
Why?
|
| Chlorambucil | 1 | 1988 | 17 | 0.020 |
Why?
|
| Tenascin | 1 | 2008 | 39 | 0.020 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2008 | 34 | 0.020 |
Why?
|
| Immunoglobulins | 2 | 1985 | 97 | 0.020 |
Why?
|
| Twins | 1 | 2007 | 42 | 0.020 |
Why?
|
| Infant Mortality | 1 | 2007 | 59 | 0.020 |
Why?
|
| Ischemia | 1 | 2009 | 229 | 0.020 |
Why?
|
| Tomography, Spiral Computed | 1 | 2007 | 57 | 0.020 |
Why?
|
| Dipyridamole | 1 | 1987 | 26 | 0.020 |
Why?
|
| Drug Therapy, Combination | 2 | 2003 | 648 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2009 | 453 | 0.020 |
Why?
|
| Leukopenia | 1 | 2006 | 23 | 0.020 |
Why?
|
| Calcitriol | 1 | 1987 | 106 | 0.020 |
Why?
|
| Parathyroid Hormone | 1 | 1987 | 117 | 0.020 |
Why?
|
| Walking | 1 | 2009 | 241 | 0.020 |
Why?
|
| Body Fluids | 1 | 1986 | 41 | 0.020 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2007 | 140 | 0.020 |
Why?
|
| Bronchi | 1 | 1986 | 59 | 0.020 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2009 | 435 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2009 | 866 | 0.020 |
Why?
|
| False Negative Reactions | 1 | 2005 | 63 | 0.020 |
Why?
|
| Shoulder Joint | 1 | 1987 | 110 | 0.020 |
Why?
|
| Ionomycin | 2 | 1996 | 24 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2005 | 132 | 0.020 |
Why?
|
| Butadienes | 1 | 2005 | 26 | 0.020 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2005 | 48 | 0.020 |
Why?
|
| Interleukin-1 | 2 | 1996 | 86 | 0.020 |
Why?
|
| Tetradecanoylphorbol Acetate | 2 | 1996 | 138 | 0.020 |
Why?
|
| Lung Volume Measurements | 1 | 1984 | 19 | 0.020 |
Why?
|
| Nitriles | 1 | 2005 | 68 | 0.020 |
Why?
|
| Immune Complex Diseases | 1 | 1984 | 10 | 0.020 |
Why?
|
| Cell Nucleolus | 1 | 1984 | 14 | 0.020 |
Why?
|
| Cyclin D1 | 1 | 2004 | 37 | 0.020 |
Why?
|
| Fas Ligand Protein | 1 | 2004 | 64 | 0.020 |
Why?
|
| Carbon Monoxide | 1 | 2005 | 58 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2004 | 97 | 0.010 |
Why?
|
| Heme Oxygenase (Decyclizing) | 1 | 2004 | 11 | 0.010 |
Why?
|
| Stress Fibers | 1 | 2004 | 10 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2007 | 1046 | 0.010 |
Why?
|
| Brain | 1 | 1995 | 2176 | 0.010 |
Why?
|
| HLA-DQ beta-Chains | 1 | 2003 | 5 | 0.010 |
Why?
|
| Cell Size | 1 | 2004 | 76 | 0.010 |
Why?
|
| CTLA-4 Antigen | 1 | 2004 | 45 | 0.010 |
Why?
|
| HLA-DQ Antigens | 1 | 2003 | 19 | 0.010 |
Why?
|
| Heme Oxygenase-1 | 1 | 2004 | 40 | 0.010 |
Why?
|
| Maternal Age | 1 | 2003 | 70 | 0.010 |
Why?
|
| Procollagen-Proline Dioxygenase | 1 | 2003 | 17 | 0.010 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2003 | 37 | 0.010 |
Why?
|
| Drug Resistance | 1 | 2004 | 223 | 0.010 |
Why?
|
| Glutathione Transferase | 1 | 2004 | 166 | 0.010 |
Why?
|
| Rest | 1 | 1982 | 78 | 0.010 |
Why?
|
| Cell Cycle Proteins | 1 | 2004 | 230 | 0.010 |
Why?
|
| Antimalarials | 1 | 1982 | 71 | 0.010 |
Why?
|
| Indomethacin | 1 | 1982 | 107 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2004 | 370 | 0.010 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2005 | 207 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2005 | 659 | 0.010 |
Why?
|
| Cell Line | 2 | 1997 | 1752 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2003 | 562 | 0.010 |
Why?
|
| Health Services Accessibility | 1 | 2005 | 581 | 0.010 |
Why?
|
| Immunoglobulin Gm Allotypes | 1 | 2001 | 103 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2004 | 718 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 1999 | 98 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2004 | 617 | 0.010 |
Why?
|
| Indians, North American | 1 | 1999 | 64 | 0.010 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 1998 | 13 | 0.010 |
Why?
|
| Biotinylation | 1 | 1998 | 27 | 0.010 |
Why?
|
| Chlorides | 1 | 1998 | 68 | 0.010 |
Why?
|
| Rh-Hr Blood-Group System | 1 | 1997 | 1 | 0.010 |
Why?
|
| Drug Contamination | 1 | 1997 | 10 | 0.010 |
Why?
|
| Chloramphenicol O-Acetyltransferase | 1 | 1997 | 26 | 0.010 |
Why?
|
| Foodborne Diseases | 1 | 1997 | 14 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 1997 | 191 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 1998 | 271 | 0.010 |
Why?
|
| Protein Binding | 1 | 1998 | 1027 | 0.010 |
Why?
|
| Mental Processes | 1 | 1995 | 22 | 0.010 |
Why?
|
| Physical Phenomena | 1 | 1994 | 10 | 0.010 |
Why?
|
| Physics | 1 | 1994 | 9 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 1994 | 25 | 0.010 |
Why?
|
| Amino Acid Chloromethyl Ketones | 1 | 1994 | 24 | 0.010 |
Why?
|
| Gene Expression | 1 | 1997 | 770 | 0.010 |
Why?
|
| Dilatation, Pathologic | 1 | 1993 | 58 | 0.010 |
Why?
|
| Mediastinum | 1 | 1993 | 39 | 0.010 |
Why?
|
| RNA | 1 | 1994 | 171 | 0.010 |
Why?
|
| Utah | 1 | 1992 | 27 | 0.010 |
Why?
|
| Psychotherapy | 1 | 1995 | 253 | 0.010 |
Why?
|
| Anxiety | 1 | 1995 | 422 | 0.010 |
Why?
|
| Carotid Artery, Internal | 1 | 1989 | 85 | 0.010 |
Why?
|
| Cerebral Angiography | 1 | 1989 | 151 | 0.010 |
Why?
|
| Antibody-Producing Cells | 1 | 1988 | 5 | 0.000 |
Why?
|
| Viral Plaque Assay | 1 | 1988 | 12 | 0.000 |
Why?
|
| Pedigree | 1 | 1988 | 159 | 0.000 |
Why?
|
| Genetic Markers | 1 | 1988 | 144 | 0.000 |
Why?
|
| alpha 1-Antitrypsin | 1 | 1988 | 61 | 0.000 |
Why?
|
| Sheep | 1 | 1988 | 128 | 0.000 |
Why?
|
| Erythrocytes | 1 | 1988 | 137 | 0.000 |
Why?
|
| Mitogens | 1 | 1987 | 45 | 0.000 |
Why?
|
| Receptors, IgG | 1 | 1988 | 94 | 0.000 |
Why?
|
| Random Allocation | 1 | 1988 | 442 | 0.000 |
Why?
|
| Neoplasm Staging | 1 | 1988 | 799 | 0.000 |
Why?
|
| Immunodiffusion | 1 | 1985 | 19 | 0.000 |
Why?
|
| Haplorhini | 1 | 1985 | 44 | 0.000 |
Why?
|
| Buttocks | 1 | 1985 | 16 | 0.000 |
Why?
|
| Forearm | 1 | 1985 | 25 | 0.000 |
Why?
|
| Immunologic Techniques | 1 | 1984 | 30 | 0.000 |
Why?
|
| Epidermis | 1 | 1985 | 42 | 0.000 |
Why?
|